Rafael Holdings Inc - Ordinary Shares - Class B

NYSE:RFL  
21.84
+1.19 (+5.76%)
Products

Rafael Pharmaceuticals Receives FDA Fast Track Designation For Cpi-613 For Treatment Of Pancreatic Cancer

Published: 11/10/2020 14:17 GMT
(RFL) - Rafael Pharmaceuticals Receives FDA Fast Track Designation for Cpi-613® (devimistat) for the Treatment of Pancreatic Cancer.